Tumor News and Research

RSS

Cancer cells utilize fructose as an alternative to glucose for fueling growth: Study

A study published in the August issue of Cancer Research has resulted in several premature and potentially misleading conclusions when it comes to fructose and its effect on pancreatic tumor cells. Unfortunately, the media covering this story, and even the authors, have been too quick to extrapolate the results of laboratory research on pure fructose to real-world conditions, which is not appropriate or helpful to consumers.

4 Aug 2010

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

What As scientists understand more about a tumor's underlying biology, personalized medicine is emerging as the new patient management paradigm. This year, the American Association for Cancer Research will host its fourth Molecular Diagnostics in Cancer Therapeutic Development: Challenges and Horizons conference at the Sheraton Denver Downtown Hotel in Denver, Colo. This meeting regularly draws representatives from academia and industry to discuss the latest in diagnostic tools and emerging therapies.

4 Aug 2010

BCM collaborates with Roche NimbleGen for high throughput exome capture technology

The Baylor College of Medicine Human Genome Sequencing Center has standardized its target enrichment human disease research studies on Roche NimbleGen Sequence Capture Exome technology. The Baylor HGSC will sequence over 5,000 exomes in the next two years to identify genetic variants underlying multiple human diseases and will employ NimbleGen SeqCap EZ Exome and customized NimbleGen exome designs as the exome capture technology of choice. More than 15 different diseases will be investigated by Baylor HGSC, including brain, liver, pancreatic, colon, ovarian and bladder cancers, heart disease, diabetes, autism, and other inherited diseases with the goal of better understanding causative mutations and their impact on these diseases.

4 Aug 2010

Accuray receives Shonin approval to market CyberKnife G4 Robotic Radiosurgery System

Accuray Incorporated, a global leader in the field of radiosurgery, announced today it received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the CyberKnife G4 Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive of head and neck. The System will be marketed in Japan as the "CyberKnife Radiosurgery System."

3 Aug 2010

Curis reports net loss of $2.1 million for second-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2010.

3 Aug 2010

First patient treated in Phase Ib expansion study of CUDC-101

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase Ib expansion study for CUDC-101 in patients with advanced head and neck, gastric, breast and liver cancers.

3 Aug 2010

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

Northwest Biotherapeutics, Inc. today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme ("GBM"), the most rapid and lethal type of brain cancer, were treated with NWBT's DCVax®-Brain personalized immune therapy.

3 Aug 2010

Research findings help shape long-term follow-up strategies for early stage lung cancer patients

In patients with non-small cell lung cancer, five-year disease-free survival is currently the benchmark of cure. However, there are two issues that remain with the follow-up standards: (1) When can cure be declared with confidence and (2) for how long should follow-up examination be continued?

3 Aug 2010

Toxic protein in bee venom improves liposome encapsulated drug effectiveness

The next time you are stung by a bee, here's some consolation: a toxic protein in bee venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs or dyes, such as those already used to treat or diagnose cancer. This research, described in the August 2010 print issue of the FASEB Journal, shows how modified melittin may revolutionize treatments for cancer and perhaps other conditions, such as arthritis, cardiovascular disease, and serious infections.

3 Aug 2010

Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma

The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma. This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies.

3 Aug 2010

Study shows prevalence, severity of dyspnea in long-term lung cancer survivors

With the growing number of long-term lung cancer survivors, research is needed to identify and address cancer survivorship issues. One of the most common and debilitating symptoms among lung cancer patients is dyspnea, or shortness of breath. As most studies of dyspnea have reviewed patients with active lung cancer or immediately after treatment, the prevalence of dyspnea over the long-term once treatment has been completed is not well characterized.

3 Aug 2010

Particles of iron oxide enhance tumor visibility through MRI

Tiny particles of iron oxide could become tools for simultaneous tumor imaging and treatment, because of their magnetic properties and toxic effects against brain cancer cells. In mice, researchers from Emory University School of Medicine have demonstrated how these particles can deliver antibodies to implanted brain tumors, while enhancing tumor visibility via magnetic resonance imaging (MRI).

3 Aug 2010

NCI awards LSUHSC-NOLA Louisiana Tumor Registry $12 million SEER contract

The Louisiana Tumor Registry (LTR) at the LSU Health Sciences Center New Orleans School of Public Health has been awarded a $12 million contract over seven years by the National Cancer Institute to continue its work as a SEER (Surveillance, Epidemiology and End Results) Program-designated cancer registry. There are 18 competitively awarded SEER cancer registries in the United States.

3 Aug 2010

Alphavirus vector induce immune responses in people with advanced cancer: Researchers

There are several challenges to be overcome if therapeutic anticancer vaccines, which are designed to boost the patient's anticancer immune response, are to be successfully developed. For example, the viruses used to deliver the tumor protein to the patient's immune system are themselves targeted by the patient's immune system, inducing neutralizing and suppressive responses. But now, a team of researchers, led by Michael Morse, at Duke University Medical Center, Durham, has developed a way to overcome these neutralizing and suppressive responses by using an alphavirus packaged in virus-like replicon particles.

3 Aug 2010

Alphavirus vaccine blocks tumor growth in advanced cancer: Research

An experimental vaccine based on a virus that causes encephalitis in the wild appears to block tumor growth in some cases of advanced cancer, according to researchers at Duke University Medical Center. Scientists say the vaccine is able to stimulate an immune response, even in the face of profound immune system suppression, a condition most patients with advanced cancer experience.

3 Aug 2010

Research findings could lead to new drugs that reduce severity of blood infections leading to sepsis

Scientists have made an important discovery that could lead to new drugs that reduce the severity of blood infections leading to sepsis. Research presented in the August 2010 issue of Journal of Leukocyte Biology shows how interfering with the function of the cell membrane protein called "Programmed Death 1" (PD-1) improves survival in a clinically relevant model of severe infection.

2 Aug 2010

BGU Professor awarded grant to develop target-specific, anti-cancer drugs

Ben-Gurion University of the Negev Professor Varda Shoshan-Barmatz has been awarded a three-year, $600,000 grant from the U.S. Leukemia & Lymphoma Society to develop target-specific, anti-cancer drugs.

2 Aug 2010

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.

2 Aug 2010

Researchers discover mechanism linking H. pylori infection and stomach cancer

Researchers have discovered a mechanism by which Helicobacter pylori, the only known cancer-causing bacterium, disables a tumor suppressor protein in host cells.The new study, in the journal Oncogene, reports the discovery of a previously unknown mechanism linking H. pylori infection and stomach cancer, the second leading cause of cancer deaths worldwide.

2 Aug 2010

Scientists identify way to regulate uncontrolled growth of blood vessels

Researchers at the University of California, San Diego School of Medicine have identified a new way to regulate the uncontrolled growth of blood vessels, a major problem in a broad range of diseases and conditions.

2 Aug 2010

Tumor News and Research

Cancer cells utilize fructose as an alternative to glucose for fueling growth: Study

Premier international conference to discuss latest diagnostic tools, emerging therapies for personalized medicine

BCM collaborates with Roche NimbleGen for high throughput exome capture technology

Accuray receives Shonin approval to market CyberKnife G4 Robotic Radiosurgery System

Curis reports net loss of $2.1 million for second-quarter 2010

First patient treated in Phase Ib expansion study of CUDC-101

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

Research findings help shape long-term follow-up strategies for early stage lung cancer patients

Toxic protein in bee venom improves liposome encapsulated drug effectiveness

Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma

Study shows prevalence, severity of dyspnea in long-term lung cancer survivors

Particles of iron oxide enhance tumor visibility through MRI

NCI awards LSUHSC-NOLA Louisiana Tumor Registry $12 million SEER contract

Alphavirus vector induce immune responses in people with advanced cancer: Researchers

Alphavirus vaccine blocks tumor growth in advanced cancer: Research

Research findings could lead to new drugs that reduce severity of blood infections leading to sepsis

BGU Professor awarded grant to develop target-specific, anti-cancer drugs

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

Researchers discover mechanism linking H. pylori infection and stomach cancer

Scientists identify way to regulate uncontrolled growth of blood vessels

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News